- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06865105
Undersøgelse af målrettede terapier til behandling af voksne deltagere med aktiv psoriasis arthritis
En fase 2 -multicenter, randomiseret platformundersøgelse af målrettede terapier til behandling af voksne individer med aktiv psoriasisartrit
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.
The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1G 2E8
- Rekruttering
- Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
-
Trois-Rivières, Quebec, Canada, G9A 3X2
- Rekruttering
- Centre de Recherche Musculo-Squelettique /ID# 274397
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7H 0P4
- Rekruttering
- Dr. Latha Naik Medical Professional Corporation /ID# 272803
-
-
-
-
California
-
Huntington Beach, California, Forenede Stater, 92648-5994
- Rekruttering
- Newport Huntington Medical Group /ID# 272764
-
Kontakt:
- Site Coordinator
- Telefonnummer: 714-923-7112
-
-
Florida
-
Avon Park, Florida, Forenede Stater, 33825
- Rekruttering
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
-
Kontakt:
- Site Coordinator
- Telefonnummer: 863-314-8555
-
Clearwater, Florida, Forenede Stater, 33765
- Rekruttering
- Clinical Research Of West Florida - Phase I Unit /ID# 273198
-
Orlando, Florida, Forenede Stater, 32819
- Rekruttering
- HMD Research LLC /ID# 273086
-
Tamarac, Florida, Forenede Stater, 33321
- Rekruttering
- West Broward Rheumatology Associates /ID# 272892
-
Tampa, Florida, Forenede Stater, 33606
- Rekruttering
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
-
Kontakt:
- Site Coordinator
- Telefonnummer: (813) 870-1292
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
-
Skokie, Illinois, Forenede Stater, 60076
- Afsluttet
- Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
-
Willowbrook, Illinois, Forenede Stater, 60527
- Rekruttering
- Willow Rheumatology and Wellness /ID# 277354
-
-
Maryland
-
Cumberland, Maryland, Forenede Stater, 21502
- Afsluttet
- Klein & Associates /ID# 272829
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Rekruttering
- Dartmouth-Hitchcock Medical Center /ID# 272702
-
Kontakt:
- Site Coordinator
- Telefonnummer: 603-650-4717
-
-
Ohio
-
Middleburg Heights, Ohio, Forenede Stater, 44130
- Rekruttering
- Paramount Medical Research and Consulting /ID# 272757
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Forenede Stater, 16635
- Rekruttering
- Altoona Center For Clinical Research /ID# 272593
-
Kontakt:
- Site Coordinator
- Telefonnummer: 814-296-6108
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38119
- Rekruttering
- Private Practice - Dr. Ramesh C. Gupta /ID# 272897
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- Rekruttering
- Tekton Research - West Gate /ID# 272765
-
Frisco, Texas, Forenede Stater, 75035
- Rekruttering
- Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
-
Houston, Texas, Forenede Stater, 77089-6142
- Rekruttering
- Accurate Clinical Research - Houston /ID# 272754
-
San Antonio, Texas, Forenede Stater, 78251
- Rekruttering
- Tekton Research, LLC /ID# 272901
-
Tomball, Texas, Forenede Stater, 77375
- Rekruttering
- DM Clinical Research - Tomball /ID# 272760
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrig, 06001
- Rekruttering
- Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
-
-
Auvergne-Rhône-Alpes
-
Caluire-et-Cuire, Auvergne-Rhône-Alpes, Frankrig, 69300
- Rekruttering
- Infirmerie Protestante De Lyon /ID# 273731
-
-
Indre-et-Loire
-
Chambray-lès-Tours, Indre-et-Loire, Frankrig, 37170
- Rekruttering
- Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
-
-
Loiret
-
Orléans, Loiret, Frankrig, 45067
- Afsluttet
- Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Frankrig, 33076
- Afsluttet
- Chu Bordeaux - Hopital Pellegrin /ID# 273390
-
-
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-068
- Rekruttering
- Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
-
-
Masovian Voivodeship
-
Pruszków, Masovian Voivodeship, Polen, 05-800
- Rekruttering
- MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
-
Warsaw, Masovian Voivodeship, Polen, 02-665
- Rekruttering
- Centrum Medyczne Reuma Park /ID# 273301
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-351
- Afsluttet
- Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
-
-
Warmian-Masurian Voivodeship
-
Elblag, Warmian-Masurian Voivodeship, Polen, 82-300
- Afsluttet
- Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
-
-
-
-
-
Uherské Hradiště, Tjekkiet, 686 01
- Rekruttering
- Medical Plus Research /ID# 272363
-
Zlín, Tjekkiet, 760 01
- Rekruttering
- PV Medical Services /ID# 272368
-
-
Brno-mesto
-
Brno, Brno-mesto, Tjekkiet, 638 00
- Rekruttering
- Revmatologie /ID# 272367
-
-
Moravian-Silesian Region
-
Hlučín, Moravian-Silesian Region, Tjekkiet, 748 01
- Rekruttering
- L.K.N. Arthrocentrum /ID# 272366
-
-
-
-
-
Budapest, Ungarn, 1027
- Rekruttering
- Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
-
Budapest, Ungarn, 1023
- Rekruttering
- Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, Ungarn, 3529
- Rekruttering
- Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
-
-
Fejér
-
Székesfehérvár, Fejér, Ungarn, 8000
- Rekruttering
- Complex Rendelo Med Zrt. /ID# 272570
-
Veszprém, Fejér, Ungarn, 8200
- Rekruttering
- Vital-Medicina /ID# 272855
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
- Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
- Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
- Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
- Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA
Exclusion Criteria:
- Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
- Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
- Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
- History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Substudy 1: Risankizumab Monotherapy
Participants will receive risankizumab |
Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 1: Lutikizumab Monotherapy
Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week. |
Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 1: Lutikizumab and Risankizumab Combination Therapy
Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 2: ABBV-701 Monotherapy
Participants will initially receive ABBV-701. |
Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 2: Risankizumab Monotherapy
Participants will receive risankizumab. |
Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 2: ABBV-701 and Risankizumab Combination Therapy
Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms. |
Subcutaneous (SC) Injection Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 3: ABBV-547 Dose A
Participants will receive ABBV-547 Dose A. |
Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 3: ABBV-547 Dose B
Participants will receive ABBV-547 Dose B. |
Subcutaneous (SC) Injection |
|
Eksperimentel: Substudy 3: ABBV-547 Dose C
Participants will receive ABBV-547 Dose C. |
Subcutaneous (SC) Injection |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Tidsramme: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:
|
At Week 16
|
|
Number of Participants With Adverse Events (AEs)
Tidsramme: Up to Week 52
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to Week 52
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Tidsramme: At Week 16
|
A participant was classified as achieving MDA if 5 of the following 7 criteria were met:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Tidsramme: At Week 16
|
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:
|
At Week 16
|
|
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Tidsramme: At Week 16
|
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:
|
At Week 16
|
|
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
Tidsramme: At Week 16
|
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%. |
At Week 16
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: ABBVIE INC., AbbVie
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- M25-191
- 2024-519291-11 (Substudy 1) (Anden identifikator: EU CT)
- 2026-525937-21 (Substudy 2) (Anden identifikator: EU CT)
- 2026-527719-41 (Substudy 3) (Anden identifikator: EU CT)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-delingsadgangskriterier
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .